Atai Life Sciences down 12% after hours on mid-stage failure of schizophrenia asset

Atai Life Sciences down 12% after hours on mid-stage failure of schizophrenia asset

Recognify Life Sciences Provides Update on Phase 2b Trial of Inidascamine in Patients with Cognitive Impairment Associated with Schizophrenia - ATAI Life Sciences (NASDAQ:ATAI)

Initial results demonstrate numerical improvement of cognitive and functional measures with inidascamine across both active treatment arms compared to placebo, but did not meet statistical significance on the primary endpoint Inidascamine continues to exhibit a favorable safety and tolerability profile Full data set, including secondary endpoints and subgroup analyses will be forthcoming SOUTH SAN FRANCISCO, July 25, 2025 (GLOBE NEWSWIRE) -- Rec…